Kura Oncology, Inc. $KURA Shares Acquired by Jacobs Levy Equity Management Inc.

Jacobs Levy Equity Management Inc. raised its position in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 57.9% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 1,544,113 shares of the company's stock after purchasing an additional 566,193 shares during the period. Jacobs Levy Equity Management Inc. owned 1.78% of Kura Oncology worth $10,191,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Wealth Enhancement Advisory Services LLC acquired a new position in Kura Oncology in the 1st quarter valued at about $139,000. Rhumbline Advisers grew its position in shares of Kura Oncology by 5.2% during the first quarter. Rhumbline Advisers now owns 105,206 shares of the company's stock worth $694,000 after buying an additional 5,215 shares in the last quarter. Hsbc Holdings PLC grew its position in shares of Kura Oncology by 26.5% during the first quarter. Hsbc Holdings PLC now owns 54,491 shares of the company's stock worth $351,000 after buying an additional 11,406 shares in the last quarter. BNP Paribas Financial Markets grew its position in shares of Kura Oncology by 969.9% during the fourth quarter. BNP Paribas Financial Markets now owns 163,559 shares of the company's stock worth $1,425,000 after buying an additional 148,272 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Kura Oncology by 7.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 131,718 shares of the company's stock worth $1,147,000 after buying an additional 9,050 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on KURA shares. Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research note on Friday, June 20th. Mizuho decreased their target price on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, May 19th. Cantor Fitzgerald restated an "overweight" rating on shares of Kura Oncology in a research note on Thursday, June 26th. JMP Securities decreased their target price on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a research note on Monday, August 11th. Finally, Wall Street Zen upgraded Kura Oncology from a "sell" rating to a "hold" rating in a research note on Sunday, August 17th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Kura Oncology has an average rating of "Moderate Buy" and a consensus target price of $24.10.

Kura Oncology Stock Performance

Shares of NASDAQ:KURA traded down $0.63 during trading on Friday, reaching $8.19. The company had a trading volume of 1,579,559 shares, compared to its average volume of 1,941,540. The firm has a market capitalization of $710.87 million, a price-to-earnings ratio of -3.62 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.16 and a quick ratio of 6.16. The stock's fifty day moving average price is $6.91 and its 200 day moving average price is $6.58. Kura Oncology, Inc. has a fifty-two week low of $5.41 and a fifty-two week high of $21.40.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analyst estimates of $64.95 million. As a group, equities research analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Transactions at Kura Oncology

In other Kura Oncology news, CEO Troy Edward Wilson acquired 50,000 shares of the business's stock in a transaction on Monday, September 8th. The stock was purchased at an average price of $8.20 per share, for a total transaction of $410,000.00. Following the completion of the transaction, the chief executive officer owned 100,968 shares of the company's stock, valued at $827,937.60. The trade was a 98.10% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.40% of the company's stock.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.